Treatment Strategy for Rectal Cancer Patients With Inguinal Lymph Node Metastasis
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND/AIM: To investigate the impact of inguinal lymph node dissection (ILND) following neoadjuvant chemoradiotherapy (NACRT) for rectal cancer patients with ILN metastasis.
PATIENTS AND METHODS: Forty-three patients with rectal cancer underwent NACRT followed by curative surgery between January 2005 and December 2016. Seven patients underwent ILND after NACRT for clinically-positive ILN metastasis (ILND (+) group), while the remaining 36 did not receive ILND for clinically negative ILN metastasis (ILND (-) group). Their outcomes were retrospectively analyzed.
RESULTS: Only one patient in the ILND (+) group had a local recurrence at six years after surgery. The 5-year recurrence-free survival was 100% and 65.4% in the ILND (+) and ILND (-) groups, respectively (p=0.09), and the 5-year overall survival was 100% and 83.2%, respectively (p=0.32).
CONCLUSION: ILND following NACRT seems effective for rectal cancer patients with ILN metastasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Anticancer research - 39(2019), 10 vom: 30. Okt., Seite 5767-5772 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ueta, Koji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.10.2019 Date Revised 07.10.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/anticanres.13779 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301779805 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301779805 | ||
| 003 | DE-627 | ||
| 005 | 20231225105332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/anticanres.13779 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1005.xml |
| 035 | |a (DE-627)NLM301779805 | ||
| 035 | |a (NLM)31570480 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ueta, Koji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment Strategy for Rectal Cancer Patients With Inguinal Lymph Node Metastasis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2019 | ||
| 500 | |a Date Revised 07.10.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a BACKGROUND/AIM: To investigate the impact of inguinal lymph node dissection (ILND) following neoadjuvant chemoradiotherapy (NACRT) for rectal cancer patients with ILN metastasis | ||
| 520 | |a PATIENTS AND METHODS: Forty-three patients with rectal cancer underwent NACRT followed by curative surgery between January 2005 and December 2016. Seven patients underwent ILND after NACRT for clinically-positive ILN metastasis (ILND (+) group), while the remaining 36 did not receive ILND for clinically negative ILN metastasis (ILND (-) group). Their outcomes were retrospectively analyzed | ||
| 520 | |a RESULTS: Only one patient in the ILND (+) group had a local recurrence at six years after surgery. The 5-year recurrence-free survival was 100% and 65.4% in the ILND (+) and ILND (-) groups, respectively (p=0.09), and the 5-year overall survival was 100% and 83.2%, respectively (p=0.32) | ||
| 520 | |a CONCLUSION: ILND following NACRT seems effective for rectal cancer patients with ILN metastasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Inguinal lymph node | |
| 650 | 4 | |a NACRT | |
| 650 | 4 | |a Rectal cancer | |
| 700 | 1 | |a Matsuda, Takeru |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Kimihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Mukohyama, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuda, Yoshiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kanaji, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Oshikiri, Taro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Tetsu |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kakeji, Yoshihiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 39(2019), 10 vom: 30. Okt., Seite 5767-5772 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2019 |g number:10 |g day:30 |g month:10 |g pages:5767-5772 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/anticanres.13779 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2019 |e 10 |b 30 |c 10 |h 5767-5772 | ||